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Abstract
Chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) causes substantial morbidity afflicting approximately 10% of
adult males. Treatment is often empirical and ineffective since the etiology is unknown. Other prostate and genitourinary
diseases have genetic components suggesting that CP/CPPS may also be influenced by genetic predisposition. We recently
reported a highly polymorphic short tandem repeat (STR) locus near the phosphoglycerate kinase gene within Xq11^13.
Because this STR is in a region known to predispose towards other prostate diseases, we compared STR polymorphisms in
120 CP/CPPS patients and 300 control blood donors. Nine distinct allele sizes were detected, ranging from 8 to 15 repeats of
the tetrameric STR plus a mutant allele (9.5) with a six base deletion in the flanking DNA sequence. The overall allele size
distribution in the CP/CPPS patients differed from controls (Chi-square = 19.252, df = 8, P = 0.0231). Frequencies of two
specific alleles, 9.5 and 15, differed significantly in CP/CPPS vs. control subjects and allele 10 differed with marginal
significance. Alleles 9.5 and 10 were both more common in CP/CPPS patients than controls while allele 15 was less common.
These observations suggest that Xq11^13 may contain one or more genetic loci that predispose toward CP/CPPS. Further
investigations involving family studies, larger patient populations, and other control groups may help elucidate this potential
genetic predisposition in CP/CPPS. ß 2002 Elsevier Science B.V. All rights reserved.
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1. Introduction
‘Prostatitis’ is the diagnosis given to many men
who present with pain referable to the lower genito-
urinary tract and perineum [1^3]. In 1978^79, pros-
tatitis accounted for approximately 25% of outpa-
tient visits for genitourinary complaints [4]. Of
12 760 000 visits to urologists in 1991, 5.3% were
for prostatitis. Prostatitis ranked fourth of 20 diag-
noses given for visits to urologists [4]. Prostatitis was
a diagnosis in 2^7 million visits annually from 1990^
96, including 8% of visits to urologists and 1% of all
primary care visits [5,6]. A survey of male residents
found that the overall prevalence rate of a physician-
assigned diagnosis of prostatitis was 9%, similar to
rates of ischemic heart disease and diabetes based on
a random sampling survey of residents in Olmsted
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County, MN, USA [7]. Depending on their age, men
with a previous diagnosis of prostatitis had a 20^50%
risk for recurrent episodes.
The current consensus classi¢cation of prostatitis
syndromes includes four categories: acute bacterial
prostatitis, chronic bacterial prostatitis, asympto-
matic in£ammatory prostatitis, and chronic prostati-
tis/chronic pelvic pain syndrome (CP/CPPS) [8,9].
Acute bacterial prostatitis presents with acute symp-
toms of bacterial urinary tract infection caused by
the standard uropathogens. Patients may also have
systemic symptoms of infection, but most respond
promptly to appropriate antibacterial therapy. Re-
current episodes of bacteriuria caused by the same
uropathogen constitute a hallmark of chronic bacte-
rial prostatitis. Between episodes of bacteriuria, care-
ful culture methods can prove that the focus of in-
fection is the prostate gland. Patients with chronic
bacterial prostatitis are unusual, constituting less
than 7% of patients attending our chronic prostatitis
clinic [10]. Asymptomatic in£ammatory prostatitis is
diagnosed during evaluation of other conditions, for
example based on ¢nding in£ammatory in¢ltrates in
a prostate biopsy obtained for evaluation of possible
prostate cancer. CP/CPPS is the most common type
of chronic prostatitis accounting for more than 90%
of patients with symptoms. Patients su¡er debilitat-
ing symptoms, but they do not have bacteriuria or
clear evidence of infection with the possible excep-
tion of recent PCR-based ¢ndings [11]. Because we
have limited understanding of the causes of this syn-
drome, therapy is entirely empirical and often unsat-
isfactory.
Many patients ask if their family history is an
important determinant of their own risk for develop-
ing prostate disease. Genetic background is impor-
tant in prostate cancer that has been associated with
a number of genes on the X chromosome [12^18]. In
contrast to the well-described pedigrees of patients
with familial prostate cancer, we have limited infor-
mation about the potential genetic factors associated
with CP/CPPS.
Genetic predisposition is implicated in many uro-
genital diseases including kidney disease [19^22].
Similar genetic factors may in£uence the risk for bac-
terial urinary tract infections characteristic of acute
and chronic bacterial prostatitis in men. In women,
the risk of recurrent urinary tract infection clearly
re£ects genetic background, e.g. blood group antigen
and secretor status [23^26]. Thus, it is reasonable to
expect that genetic factors may be important in CP/
CPPS.
Both embryonic and later development of the
prostate require presence of androgens and androgen
receptors (ARs). Interestingly, the X chromosome
contains a polymorphic gene for the AR that is lo-
cated near one of the putative prostate cancer loci
[12^16,18,27^29]. Although literature searches re-
vealed no reports of genetic predisposition to CP/
CPPS, 23% of patients attending our clinic reported
a history of ¢rst-degree male relatives with prostatitis
compared to a rate of 9% described in the overall
male population [7]. Those histories did not exclude
father/son relationships. The high rate of prostatitis
among relatives of patients was similar to the expe-
rience of the Prostatitis Foundation, where a 20%
rate was reported among respondents to an internet
survey (http://prostatitis.org/aboutpf.html). Patient
interviews suggested in£uence from the maternal lin-
eage (http://prostatitis.freeservers.com). We identi-
¢ed a polymorphic short tandem repeat (STR) on
the X chromosome that allowed us to evaluate if
there is a potential genetic predisposition to CP/
CPPS.
Phosphoglycerate kinase (PGK; ATP:3-phospho-
D-glycerate 1-phosphotransferase, EC 2.7.2.3) is a
metabolic housekeeping enzyme located within
Xq11^Xq13. The PGK gene is closely linked [30] to
AR within a region implicated in a number of X-
linked urologic disorders. These disorders include:
familial predisposition to prostate cancer [14^16], an-
drogen insensitivity [17,31] and perineal hypospadias
[32,33]. Initially, we identi¢ed a highly polymorphic
STR DNA sequence near the PGK gene [34,35]. In
over 500 people tested, 10 distinct alleles were de-
tected with frequencies ranging from 2% to 38%.
Since the locus is X-linked, heterozygosities must
be measured in women, and heterozygosity is gener-
ally s 80%. Herein, we report our ¢ndings compar-
ing the distributions of STR alleles in patients with
CP/CPPS to a control population. Our ¢ndings are
consistent with the clinical suggestion that there may
indeed be an inherited predisposition for some men
to develop CP/CPPS.
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2. Materials and methods
2.1. CP/CPPS patient population and clinical
evaluation
Subjects with CP/CPPS were recruited from pa-
tients attending the University of Washington Pros-
tatitis Clinic following a protocol approved by the
University of Washington Human Subjects Commit-
tee. No subject had taken antimicrobial agents for 6
weeks prior to enrollment and patients with docu-
mentation of bacteriuria were excluded. Following
a standardized history and physical examination,
we obtained specimens for urethral Gram stain and
cultures for Neisseria gonorrhoea, Chlamydia tracho-
matis, genital mycoplasmas, and Trichomonas vagina-
lis [36,37]. Each patient had a uro£ow study and
residual urine determination by ultrasound to ex-
clude signi¢cant structural or functional abnormal-
ities of the lower urinary tract. We also excluded
potential subjects who had uropathogens localized
to the prostate by the four-glass urine test (chronic
bacterial prostatitis), urethritis (s 5 leukocytes/400U
¢eld on the Gram-stained urethral smear), or positive
urethral cultures for C. trachomatis or T. vaginalis.
2.2. CP/CPPS patient specimens
Each CP/CPPS patient underwent prostatic biopsy
using a perineal, rather than a transrectal, approach
to prevent microbial contamination. Biopsies were
obtained by the double-needle biopsy technique de-
scribed previously [11]. Control samples were ob-
tained of the perineal skin surface and of peri-pro-
static tissues. Prostate biopsies were sent to the PCR
laboratory in sterile containers within 30 min of col-
lection.
2.3. Control population
Patients attending the general hospital clinics were
sampled on three consecutive days in batches of ap-
proximately 100. Patient data were screened to deter-
mine ethnic information, sex, diagnoses, and clinics
attended. Male samples in the control group were
not used if there was a history of prostate disease
in their medical records. While representative of
our general clinical population, we cannot exclude
unreported histories or predispositions toward pros-
tate disease among members of the control group.
Female blood samples were included in the control
group since, for the X-linked PGK STR, female sam-
ples have twice the information content of male sam-
ples. Also, female samples would have arrived at the
clinic for reasons other than prostate disease making
these a useful sampling of the gene pool within our
clinical patient population. Since men inherit their X
chromosomes from their mothers, there is no reason
a priori to expect population di¡erences comparing
male and female PGK STR distributions and no dif-
ferences were found in the present study.
Stoppered tubes containing ethylenediaminetetra-
acidic acid and disposed blood drawn from 300 men
and women were obtained from the University of
Washington Medical Center Central Processing fa-
cility. Blood was drawn between 8 and 48 h prior
to DNA isolation. DNA was extracted from 300
control blood samples (132 male, 168 female) and
prostatic biopsy specimens of 120 prostatitis patients.
2.4. PCR assays
Based on the reported PGK £anking DNA se-
quence [35] PCR primers were constructed to amplify
the PGK 3P STR. The primer sequences used in the
current study were: PGK11: 5P-TGGGCAACAGT-
GAGACTCT-3P ; PGK12: 5P-CAACTACAGAAC-
AGCAGGTA-3P.
Thermal cycles were: 94‡C for 5 min, then 35
cycles of 94‡C for 1 min, 62‡C for 1 min, 72‡C for
1 min followed by extension at 72‡C for 7 min. PCR
bu¡er consisted of 10 mM Tris^HCl (pH 8.3) 50 mM
KCl, and 1.0 mM MgCl2. Initially, MgCl2 concen-
trations were varied over the range 0.5^5 mM, with
1.0 mM proving optimal. Annealing temperatures
were initially varied from 60‡C to 70‡C, with 62‡C
proving optimal. Taq polymerase (Perkin-Elmer;
Norwalk, CT, USA, 5 U/100 Wl of reaction) was
used as the thermostable enzyme.
2.5. Allele size determination
We synthesized £uorescent PCR primers comple-
mentary to an STR in the 3P £ank of the PGK1 gene.
The ampli¢ed products were electrophoresed, sized
and sequenced using a LiCor automated sequencer
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(Genereader, 4,000; Lincoln, NE, USA). Allelic siz-
ing at the PGK STR locus, coupled with high-
throughput £uorescent PCR product detection, fa-
cilitated rapid typing of samples. Approximately 50
PCR products could be electrophoresed and detected
in a little over 30 min. Electrophoretic gels in this
system have been reloaded up to ¢ve times with little
deterioration in the signal-to-noise ratio. Fluorescent
detection of PCR products was made possible by
incorporating 1^2 pmol IRD41 (absorbance maxi-
mum 795 nm, £uorescence maximum 833 nm; East-
man Kodak, Rochester, NY, USA)-labeled PGK12
primer synthesized at LiCor (Lincoln, NE, USA).
3. Results
3.1. Polymorphism and hemizygosity
Nine distinct alleles were detected including eight
Fig. 1. Schematic diagram of the PGK1 STR region of the X chromosome. Top, the Xq12^Xq13 region of the X chromosome.
DXS991, GeneMap’99 anchor marker; MTHFD, 5,10-methylenetetrahydrofolate dehydrogenase; GTF1A1, general transcription fac-
tor IIA; AR, androgen receptor gene; DXS983, anchor marker; LDLR, low density lipoprotein receptor; PGK1, phosphoglycerate
kinase 1 gene; DXS995, anchor marker; TBG, thyroxin-binding globulin. There are some uncertainties in gene order in this region of
the X chromosome. The inset shows a digital image of a LiCor £uorescent gel. L, ladders containing all known PGK1 STR alleles.
Ladders were run in every fourth lane for the 420 subjects studied. Single-band PCR products for male subjects were sized by com-
parison with the known ladder band DNA fragments.
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based on variations in the number of TATC repeats
(Figs. 1 and 2). Since the PGK1 STR is located on
the X chromosome, males exhibit one allele each,
while women each exhibit two alleles. Alleles were
named for the number of STR repeats they con-
tained, or for their size. The allele frequency distri-
butions are shown in the Table 1.
None of the male tissue or blood samples demon-
strated more than a single PGK STR allele. A single
allele per male sample was consistent with the X
chromosomal location of the PGK STR and also
suggested that cross-contamination of these samples
was infrequent since cross-contamination would lead
to multiple allele sizes appearing in male samples.
3.2. Cases vs. control distributions
The median allele size among 120 CP/CPPS cases
was 11 (range 8^14). This was lower than the median
allele size of 12 (range 8^15) among the 300 control
subjects (Mann^Whitney U = 14912, P = 0.006). The
overall distribution of alleles (Fig. 1) was also di¡er-
ent comparing CP/CPPS patients and controls (Chi-
square = 19.252, df = 8, P = 0.0231).
3.3. Signi¢cance tests of individual alleles
Analysis of individual alleles showed that the dif-
ference between CP/CPPS patients and controls was
largely accounted for by three alleles, 9.5, 10 and 15.
Based on previously reported DNA sequence data,
the 9.5 allele is actually a mutant, 11 allele (11 re-
peats of 4 bp each) with a 6 bp deletion in sequence
£anking the repeat [34]. Only 6 (1.4%) of 420 total
subjects exhibited the 9.5 allele. Of these six patients,
¢ve were in the CP/CPPS group. Thus, 4.2% of the
120 CP/CPPS patients had the 9.5 allele compared to
only 0.3% of the 300 controls (Chi-square = 8.944,
df = 1, P = 0.0028). Of the 420 total subjects who
had distinct alleles, 123 (29%) exhibited the 10 allele.
These 123 subjects with the 10 allele included 35.8%
of 120 CP/CPPS patients compared to 26.7% of 300
controls (Chi-square = 3.478, df = 1, P = 0.062). Of
the 420 total subjects who exhibited distinct alleles,
10 had the 15 allele. All 10 were in the control group.
Thus, the 15 allele was present in 3.3% of the 300
controls but in none of the 120 CP/CPPS cases (Chi-
square = 4.098, df = 1, P = 0.0429). There were no sig-
ni¢cant di¡erences in the frequencies of the 8, 9, 11,
12, 13 and 14 alleles between cases and controls. Of
these, alleles 8 and 9 were relatively rare (6 5%) in
the overall population of 420 subjects.
4. Discussion
Our data suggest that certain men may have a
Fig. 2. Histogram showing the distribution of subjects with var-
ious PGK1 STR allele sizes. Light boxes, CP/CPPS patients.
Dark boxes, control blood samples. Asterisks, allele sizes with
signi¢cant or marginally signi¢cant (10 allele) di¡erences com-
paring CP/CPPS patients with controls.
Table 1
PGK1 STR allele sizes in CP/CPPS patients and controls
Number of repeats 8 9 9.5 10 11 12 13 14 15
Controls (%) 2.0 2.7 0.3 26.7 22.3 26.0 10.7 6.0 3.3
n = 300 (6) (8) (1) (80) (67) (78) (32) (18) (10)
CP/CPPS (%) 2.5 2.5 4.2 35.8 21.7 20.0 7.5 5.8 0
n = 120 (3) (3) (5) (43) (26) (24) (9) (7) (0)
Signi¢cancea 0.75 0.92 6 0.01 0.06 0.88 0.2 0.32 0.95 0.04
aChi-square for individual alleles. For the overall distribution, Chi-square = 19.252, df = 8, P = 0.0231.
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genetic predisposition to develop CP/CPPS. Signi¢-
cant associations of certain alleles at the X-linked
PGK1 STR ¢t with the clinical observation that
many CP/CPPS patients have blood relatives with
prostatitis, particularly in their maternal pedigrees
(http://prostatitis.freeservers.com). This potential
predisposition may be located in a speci¢c region
of the X chromosome near other sites that appear
to be critical for prostate growth and development,
as well as for development of some familial prostate
cancers.
The PGK1 gene is located within the DXS983^
DXS995 interval of GeneMap’99 at 94.4^97.4 cM.
AR is in the adjacent interval, DXS991^DXS983 at
86.9^94.4 cM. Ordering of loci is still uncertain, but
the distance between PGK1 and AR may be rela-
tively short. We examined cross-over frequencies at
the GenLink, Human Meiotic Map (http://www.gen-
link.wustl.edu/). Using the marker DXS1275 as a
reference present in overlapping intervals, we calcu-
lated that there were two cross-over events between
AR and PGK1 out of 227 jointly informative meio-
ses. AR is the only obvious candidate for genitouri-
nary tract e¡ects in this region of the chromosome,
but there are almost certainly uncharacterized genes
in the vicinity making it premature to assign our
results to any known gene.
Literature searches revealed no previous reports
suggesting a genetic predisposition to develop CP/
CPPS. However, patient interviews frequently sug-
gest a¡ected relatives on the maternal side. Of 100
patients responding to a survey, 18% reported an
a¥icted maternal grandfather compared with 9%
who had paternal grandfathers with CP/CPPS. Of
the same 100 patients, 14% reported maternal uncles
with CP/CPPS while 0% reported CP/CPPS a¥icted
paternal uncles. These observations are consistent
with an X-linked predisposing factor(s) although
much further work will be needed to con¢rm or
deny this. Since the X chromosome has only a small
region of homology with the Y chromosome, most
X-linked genes lack compensatory homologues if
there is a de¢cient or otherwise marginally active
gene.
Males who are castrated or otherwise lose testicu-
lar function prior to puberty are termed eunuchs.
Eunuchs have prostate glands but do not develop
the major prostate diseases: benign prostatic hyper-
plasia, prostate cancer and CP/CPPS. These observa-
tions suggest that hormones produced by the testes,
speci¢cally testosterone and, if 5-K reductase is ac-
tive, dihydrotestosterone (dHT), may determine vul-
nerability to prostate diseases.
Hormones and their receptors play important roles
in many stages of prostate development. In the sec-
ond month of embryo development, placental human
chorionic gonadotropin (hCG) induces Leydig cells
at the genital ridge to secrete testosterone [38]. Tes-
tosterone, if converted to dHT by an active 5-K re-
ductase, promotes masculinization of the bi-potential
gonads in the third month of gestation, as well as
promoting prostate di¡erentiation and masculiniza-
tion of the external genital structures. Leydig cell
testosterone secretion, while controlled by placental
hCG during the critical stage of sexual di¡erentia-
tion, is later controlled by fetal pituitary luteinizing
hormone. Assuming a normal AR, dHT continues to
promote prostate growth and masculinization at
puberty. Defective genes have been described at vir-
tually every stage of this developmental cascade [38].
De¢ciency in 5-K reductase or in the AR can lead to
severe interruptions in genitourinary development
early in life. Adult onset prostate diseases may re£ect
subtle variations in the activities of some of the same
genes that are crucial in early development. For these
reasons, we investigated polymorphic variation, us-
ing the PGK1 STR, in the region of the X chromo-
some where AR resides.
Since the majority of men may eventually be af-
fected by prostate disease, it is extremely di⁄cult to
identify an ideal control group for comparison with
CP/CPPS patients. We elected instead to compare
CP/CPPS cases with general clinical, control blood
samples. Lifetime incidences of prostate diseases are
still in dispute, but susceptible individuals in the con-
trol group would tend to reduce di¡erences between
CP/CPPS and controls in this study. We previously
demonstrated that the PGK1 STR allele size is so-
matically stable allowing comparisons of blood DNA
in one population with prostate tissue DNA in an-
other [34].
Mitochondrial DNA sequences suggest that hu-
mans likely evolved from a very limited population
[39,40]. We reasoned that during this early bottle-
BBADIS 62075 20-12-01
D.E. Riley, J.N. Krieger / Biochimica et Biophysica Acta 1586 (2002) 99^107104
neck in evolution, there was likely only one, or per-
haps a few variants of AR, or another gene a¡ecting
prostate development. Later, genetic drift would
have led to lineages with slightly di¡erent suscepti-
bilities to diseases such as CP/CPPS.
The results presented here are consistent with var-
iations in the Xq11^Xq13 region, perhaps AR, or
another gene, predisposing men to CP/CPPS. It
seems unlikely that variants of the housekeeping en-
zyme, PGK1, contribute to CP/CPPS predisposition.
Rather, the variant PGK1 STRs detected probably
mark ancient human lineages that would, by chance,
be expected to have subtle variations in AR or other
gene activities.
While statistically signi¢cant, di¡erences at the 9.5,
15 alleles among CP/CPPS patients vs. controls were
relatively subtle. The di¡erence for the 10 allele
(P = 0.06) is marginal and technically only signi¢cant
at 90% con¢dence. Currently, our CP/CPPS popula-
tion was not strati¢ed for di¡erences such as family
history of CP/CPPS. It is possible that populations
selected for family history may exhibit more dramat-
ic di¡erences in PGK1 STR allele types. Such studies
are underway.
In addition to Xq11^Xq13, other regions of the X
chromosome and of autosomes have been implicated
in genetic predisposition to urologic diseases, partic-
ularly prostate cancer. Hypothesizing that variant
genes implicated in other urologic diseases may
play a role in prostate embryogenesis and develop-
ment, we also plan to search for additional STRs in
those regions. It is possible that if more associations
are found, the combined typing of multiple STRs
may provide practical diagnosis of a patient’s vulner-
ability to CP/CPPS. This work is in progress.
In summary, potential genetic predispositions as-
sociated with the PGK gene, or another gene within
Xq11^Xq13, such as AR, should be further investi-
gated. This approach may provide important insights
into the pathogenesis of CP/CPPS and other prostate
diseases and open this ¢eld to powerful new genetic
techniques. Work is in progress to scan the X chro-
mosome with other polymorphic markers. Ulti-
mately, it may prove possible to use such genetic
information to predict a man’s susceptibility to CP/
CPPS or his response to possible therapeutic inter-
ventions.
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